Bristol-Myers Squibb Company (FRA:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 94.14B |
| Revenue (ttm) | 40.94B |
| Net Income (ttm) | 5.15B |
| Shares Out | n/a |
| EPS (ttm) | 2.53 |
| PE Ratio | 18.29 |
| Forward PE | 8.74 |
| Dividend | 2.22 (4.85%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 70 |
| Average Volume | 846 |
| Open | 45.27 |
| Previous Close | 45.64 |
| Day's Range | 45.27 - 45.81 |
| 52-Week Range | 36.65 - 58.50 |
| Beta | n/a |
| RSI | 65.80 |
| Earnings Date | Feb 5, 2026 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
Bristol Myers Squibb (BMY) to Provide Eliquis Free to Medicaid
Bristol Myers Squibb (BMY) to Provide Eliquis Free to Medicaid
Bristol-Myers blood thinner Eliquis offered free to Medicaid as part of U.S. pricing deal
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. cost...
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Bristol Myers Squibb (BMY) closed at $54.19 in the latest trading session, marking a +1.61% move from the prior day.
Bristol Myers Squibb (BMY) Joins New Deal to Lower Drug Prices in U.S.
Bristol Myers Squibb (BMY) Joins New Deal to Lower Drug Prices in U.S.
Bristol Myers (BMY) Enhances Access to Eliquis with Landmark Agreement
Bristol Myers (BMY) Enhances Access to Eliquis with Landmark Agreement
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much ...
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...
Bristol Myers Squibb (BMY) Set to Announce Drug Price Reduction Deal
Bristol Myers Squibb (BMY) Set to Announce Drug Price Reduction Deal
AbbVie, Bristol Myers, Merck among latest to announce U.S. drug pricing deals: Reuters
AbbVie (ABBV), Bristol Myers Squibb (BMY), Gilead (GILD), and Merck (MRK) are set to annouce U.S. drug pricing deals. Read more here.
Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2025 on Thursday, February 5, 2026. Company executives will review financial results with the investment community duri...
Building a Healthier Future Together: Strengthening Cancer Care Across Africa Through Partnership
NORTHAMPTON, MA / ACCESS Newswire / December 17, 2025 / Originally published on Bristol Myers Squibb News & PerspectivesFor many cancer patients throughout Africa, the journey to diagnosis and treatme...
Harbour BioMed, Bristol Myers More Than $1.1 Bln Deal For Next-Gen Multi-Specific Antibodies
(RTTNews) - Harbour BioMed (2142.HK) announced that it has entered into a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb. The partnership aims to discover a...
BMY Crosses Above Average Analyst Target
In recent trading, shares of Bristol Myers Squibb Co. (Symbol: BMY) have crossed above the average analyst 12-month target price of $53.71, changing hands for $54.29/share. When a stock reaches the ta...
Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored
BofA Securities upgraded Bristol Myers Squibb & Co. (NYSE: BMY), citing near-term catalysts . “What we like about BMY is the valuation coupled with our forecast for a flattish 7-year outlook with ris...
BMY: Bristol-Myers Squibb Upgraded to Buy by B of A Securities | BMY Stock News
BMY: Bristol-Myers Squibb Upgraded to Buy by B of A Securities | BMY Stock News
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Bristol Myers Squibb (BMY) Upgraded to Buy on Promising Pipeline Prospects
Bristol Myers Squibb (BMY) Upgraded to Buy on Promising Pipeline Prospects
Bristol Myers Squibb upgraded at Guggenheim on 2026 pipeline catalysts
Guggenheim upgrades Bristol Myers Squibb to buy, citing promising drug pipeline and potential 21% upside. Read more here.
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
The Best Turnaround Stock to Invest $1,000 in Right Now
Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.
Guggenheim Upgrades Bristol-Myers Squibb (BMY) to Buy, Sets New Price Target | BMY Stock News
Guggenheim Upgrades Bristol-Myers Squibb (BMY) to Buy, Sets New Price Target | BMY Stock News
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript
Bristol-Myers Squibb Co Virtual Investor Presentation on Hematology Programs Transcript
Bristol-Myers Squibb Co Virtual Investor Presentation on Hematology Programs Transcript